While β-ARs are well known to be affected during heart failure (HF) and β-AR blockers used in HF treatment, the role of α1-ARs, particularly the α1A-AR, are recent developments in offering cardioprotective and inotropic benefits during HF. This evidence concerns the gene CTBP1 and heart failure.